Ultra-high resolution optical coherence tomography of birdshot retinochoroidopathy

Birdshot retinochoroidopathy is a rare inflammatory eye disease with typical clinical presentation and strong association with the HLA-A29 allele. Characteristic appearances on fluorescein angiogram (FA), indocyanine green (ICG) angiography, and electroretinogram (ERG) have been described. However, histopathology of the disease has been rare.

The following case is an example of birdshot retinochoroidopathy imaged with ultra-high resolution optical coherence tomography (UHR-OCT), capable of 3 μm axial resolution. UHR-OCT is able to clearly delineate individual intraretinal layers (fig 1).

Case report

A 64 year old man presented to the New England Eye Center (NEEC) for progressive visual deterioration despite cataract surgery in the left eye 2 years earlier. The patient’s major complaints were difficulty seeing at night and difficulty driving. Best corrected visual acuity (BCVA) was 20/50 right eye and 20/60 left eye. Anterior eye examination revealed mild cells and flare in both eyes, a moderate cataract in the right eye, and a posterior chamber intraocular lens in the left.

Dilated fundus examination revealed mild vitritis bilaterally. The optic discs appeared slightly pale and the retinal vasculature was narrowed. Fundus appearance was consistent with the diagnosis of birdshot retinochoroidopathy (fig 2A). FA and ICG angiography were also consistent with this diagnosis (fig 2B). Six mm radial macular OCT3 scans showed bilateral epiretinal membranes (ERM), with mild thickening in the left eye. The patient subsequently tested positive for the HLA-A29 antigen. Over the next 6 months, the patient was treated for macular oedema with intravitreal Kenalog injections in both eyes, and the macular oedema subsided.

UHR-OCT images were obtained 6 months later (fig 3), at which time BCVA remained stable. Repeat fundus examination and OCT3 imaging revealed an ERM with no macular oedema and normal retinal thickness in both eyes. UHR-OCT images additionally showed photoreceptor atrophy in several areas of both eyes. RPE degeneration was present underneath areas of photoreceptor involvement. The inner retinal layers were difficult to delineate, probably because of anatomical disorganisation of these layers.

Comment

This case represents a fairly severe case of birdshot retinochoroidopathy. In a review by Gasch et al, epiretinal membrane was the second most common complication of birdshot retinochoroidopathy next to macular oedema, which our patient also had on initial presentation. ERG findings have shown Mueller and bipolar cell involvement early in the disease, while photoreceptors are affected later. The UHR-OCT images presented here show disorganisation of inner retinal layers as well as photoreceptor and RPE atrophy. Choroidal ischaemia, suggested by ICG angiography, may be the cause of RPE and photoreceptor degeneration.

We found two histopathological reports of birdshot retinochoroidopathy. One case was a blind phthisical patient. The other was a more typical yet mild case, which showed lymphocytic infiltration around the choroidal and retinal vasculature with minimal retinal disturbance. Serial UHR-OCT imaging of patients could help in understanding and following progression of macular involvement in this disease.

References


J S Schuman
UPMC Eye Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Correspondence to: Jay S Duker, MD, Ophthalmology Department, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111, USA; jduker@tufts-nemc.org
doi: 10.1136/bjo.2005.074570

Accepted for publication 29 July 2005


JGF and JSS receive royalties from intellectual property licensed by MIT to Carl Zeiss Meditec. JGF and JSS receive research support from Carl Zeiss Meditec.

A J Witkin, J S Duker
New England Eye Center, Tufts-New England Medical Center, Tufts University, Boston, MA, USA

T H Ko, J G Fujimoto
Department of Electrical Engineering and Computer Science and Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, MA, USA
Unilateral necrotising toxoplasmic retinochoroiditis as the main clinical manifestation of a peptide transporter (TAP) deficiency

Congenital HLA class I deficiency is a rare disease frequently resulting in chronic inflammation of the respiratory tract, and/or skin granulomas. The deficiency may be unnoticed for decades, so pathological outcome is relatively unpredictable. We here describe a 14 year old patient with a severe ocular toxoplasmosis who is HLA class I deficient, as a result of a homozygous mutation in the gene encoding one of the two subunits of the peptide transporter associated with antigen processing (TAP). We propose that such a defect should be investigated in patients with severe ocular toxoplasmosis without acquired immunodeficiency.

Case report

At the time of referral, the patient did not have any particular medical history except an exaggerated reaction to an intradermal tuberculin test 1 year earlier. His right eye displayed a strong reduction of acuity with anterior and posterior inflammatory lesions and pain. There was corneal inflammation with flare in the anterior chamber, anterior uveitis with cellular deposits on the corneal endothelium (keratic precipitates) but without posterior synechiae and grade B3 vitritis. A focus of chorioretinitis was just visible out posterior synechiae and grade B3 vitritis. The severity of the clinical manifestations prompted an evaluation of the patient’s immunocompetence, which appear to be normal, except that the amount of HLA class I molecules expressed on the plasma membrane of the lymphocytes was reduced 20-fold (figs 2 and 3). The parents were unrelated, but shared an identical HLA haplotype, so the patient and his brother were HLA homozygous (HLA-A*24; B*14; Cw*08; DRB1*13; DQB1*06). TAP genes, located in the HLA genetic region, were characterised, and a stop mutation in the TAPI was identified at codon 522 (sequence AAS55412.1 in GenBank), because of a C to T substitution.

The patient did not display pulmonary involvement, contrary to his elder brother who displayed a bronchial obstruction unresponsive to inhaled bronchodilators, a bacterial colonisation of the lower airways associated to asthma-like symptoms, but no bronchiectasies.
The advent of fluorocarbon silicone/acrylate co-polymer SCLs resulted in greater utility because of high gas permeability. One major criticism of SCLs has been the suboptimal visual acuity achieved when compared to CCLs. In this study we compared the best corrected visual acuity (BCVA) in patients with RGP SCLs who failed a trial of CCLs.

Method and results

The case notes of 15 patients prescribed RGP SCLs were reviewed over a 18 month period. The reasons for discontinuing CCL use included discomfort, excessive mobility, poor fit, short wearing times, and subjective lens intolerance. There were 18 eyes in 15 patients whose average age was 37 years (18–80). There were eight males and seven females.

The BCVA varied according to the pre-existing pathology. These were post-penetrating keratoplasty (seven); keratoconus (six), and herpetic scarring (two). Mean astigmatism was 9.7D (3.5–18D). CCL average BCVA was 6/18, but with SCLs was 6/9, of which eight (44%) achieved 6/9, p = 0.1, $\chi^2$ test.

The greatest improvement occurred in the keratoconus group (CCL 6/18 with CCLs; to 6/9–6/5 with SCLs); followed by the keratoconus group (with SCL 6/9 in five cases and 6/18 in two cases from pre-existing corneal scarring). In all cases the scleral lenses were well tolerated. No complications were noted.

Comment

The relatively close apposition of the cornea to a CCL provides a stable refractive interface. In a normal cornea, the centre is assumed to be spherical and regular so that a single curved CCL can be made based on keratometry readings. In corneas with highly abnormal topography such as high astigmatism, severe flattening or protrusion, thinning, and scarring, the nature of the refractive interface between the lens and corneal interface is altered because the above assumptions no longer hold true. SCLs vault the cornea, which eliminates the need for close alignment to the cornea. This compensates for very abnormal corneas giving good BCVA that can be difficult to achieve with CCLs. As the power of CCLs increases, positional stability and accuracy of fit decreases. High power CCLs tend to be bulky, thicker, and with a larger diameter that alters the centre of gravity. These CCLs tend to sag or droop with axis mislocation so vision is through the peripheral lens and not the optic zone. Induced prismatic effects cause reduced vision, lens intolerance, and discomfort. This is exacerbated by edge sensation from high edge lift. Lens instability with excessive fractional mobility on the cornea also increases the potential for complications, scarring, and intolerance. SCLs retain positional stability and tend not to be associated with the aforementioned problems.

Based on the findings of this study, we think the use of SCLs should not be prejudiced because of the perception that they are optically inferior to CCLs. The optical and therapeutic benefit of SCLs should not be underestimated. They can have an important role in management of patients where surgery is undesirable or high risk.

A Salam, B Melia

Hull and East Yorkshire Eye Hospital, Fountain Street, Anlaby Road, Hull HU3 2JZ, UK
Optometric referrals: towards a two way flow of information?

Glaucoma referrals and audited the replies. The optometrist’s letter. This might reflect better facilities for management. The institute’s referral rate (2.5%) is lower than previously reported for optometrists. This reflects a higher proportion of referrals when the optometrists actually replied to a higher percentage of letters, but there was no improvement in our referrals and audited the replies. Methods

The Institute of Optometry set minimum criteria for referrals in 2004 by typing letters on headed notepaper, including the practitioner’s name, enclosing a second copy for the GP to forward to the ophthalmologist, and enclosing text which explicitly requested a reply.

In February–April 2005 we audited referrals from 2004. Handwritten emergency referrals, which make up less than 1% of referrals, were not included.

Results

There were 181 referrals following 7164 eye examinations, which result in at least 0.5 million referrals to the hospital eye service. Optometrists only infrequently receive a reply to these referrals; possibly because 69% are handwritten on GOS18 forms, which can lack legibility and detail. Most optometrist initiated referrals take place via general practitioners (GPs), who are increasingly likely to forward the optometrist’s letter. We improved our referrals and audited the replies.

Comment

The institute’s referral rate (2.5%) is lower than previously reported for optometrists. This might reflect better facilities for monitoring (for example, ocular hypertension or managing (for example, dry eye) conditions and an ethos that encourages management when appropriate.

Although our results are only for one centre it is disappointing that, despite taking steps to encourage a reply, this is still rarely forthcoming. The proportion of referrals that receive replies is so low (13%) that we think it unlikely to be attributable to patients failing to consult the GP or ophthalmologist after referral. For the few ophthalmologists who do reply this is not an onerous task: they instruct their secretary to copy the reply to the GP to the optometrist. The NHS code of practice on confidentiality notes that explicit consent is not usually required for information disclosures that support the delivery of the patient’s care. Even if it is thought necessary to obtain consent, there is no good reason why the ophthalmologist should not obtain this. The issue of consent does not seem to be the main reason for lack of replies. A study found that ophthalmologists actually replied to a higher proportion of referrals when the optometrists had not obtained consent than when they had.

Replying to referrals helps optometrists provide continuing patient care and avoids possible errors from the optometrist relying on the patient’s recollection of the ophthalmologist’s findings. Feedback also contributes to optometrists’ professional development and helps to ensure that inappropriate referrals are minimised in the future.

Now that direct referral from primary care optometrists to secondary care ophthalmology units is becoming more commonplace, we hope that a two way flow of information will become the norm.

References


Optometric referrals: towards a two way flow of information?

The first published as 10.1136/bjo.2005.074377 on 18 November 2005. Downloaded from http://bjo.bmj.com/ on 19 November 2005 by guest. Protected by copyright.
Linezolid induced toxic optic neuropathy

Linezolid is a new oxazolidinone antibiotic with activity against many important pathogens including methicillin resistant Staphylococcus and penicillin resistant Strepococcus. We report a case of toxic optic neuropathy from chronic treatment with linezolid. Correct diagnosis and discontinuation of the drug resulted in significant recovery of vision.

Case report

A 56 year old man presented with bilateral, progressive decline in visual acuity for 6–8 months. Medical history included chronic diabetes mellitus, below the knee amputation of the right leg, hypertension, sinusitis with activity against many important pathogens, and penicillin resistant Strepococcus. We report a case of toxic optic neuropathy from chronic treatment with linezolid. Correct diagnosis and discontinuation of the drug resulted in significant recovery of vision.

Comment

Toxic optic neuropathy has been associated with numerous compounds, including exposure to ethylene glycol, methanol, isoniazid, ethambutol, and fluoroquinolone, and deficiency of vitamin B12, folate, and thiamine. Linezolid was approved by the FDA, based on studies employing 28 days of administration. There have been five cases of optic neuropathy associated with prolonged use of linezolid and more than 20 cases of peripheral neuropathy involving one individual who developed both sequelae. In previous optic neuropathy cases the duration of treatment ranged from 5–10 months at a dose of 600 mg once or twice per day. All cases were bilateral with initial vision decreased to 20/60 to counting fingers both eyes. Incontinuation of treatment, resolution of toxicity was not achieved and improvement of the optic neuropathy with significant improvement in visual acuity within 1–8 months in all patients, although

References

residual deficits in central acuity or visual evoked response may persist. Oxazolidinones inhibit bacterial protein synthesis by binding to the 70S ribosomal initiation complex. In nutritional optic neuropathies, paracentral scotomas develop from disruption in mitochondrial function in retinal ganglion cells, which are more susceptible to mitochondrial disruption. Mitochondrial dysfunction is the cause of Leber’s hereditary optic neuropathy, chloramphenicol induced bone marrow suppression, and optic neuropathy due to ethambutol and a variety of antibiotics. It is likely that the development of linezolid associated optic neuropathy, manifest by the development of central scotomas and temporal optic nerve pathology, may be the result of a similar mechanism.

It is important for ophthalmologists to perform a complete review of systems and elicit a history of prescription and non-prescription medication use. Awareness of the potential for linezolid induced optic neuropathy is important since drug withdrawal can lead to visual recovery.

K Kulkarni, L V Del Priore
Department of Ophthalmology, Columbia University, 635 West 165th Street, New York, NY 10032, USA

K Kulkarni
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854, USA

Correspondence to: Lucian V Del Priore, MD, PhD, Robert L Burch III Scholar, Department of Ophthalmology, Columbia University, 635 West 165th Street, New York, NY 10032, USA; ldelpriore@yahoo.com

doi: 10.1136/bjo.2005.074237

Accepted for publication 1 August 2005

References


www.bjophthalmol.com
Delayed progressive visual loss following wrapping of bilateral clinoidal aneurysms: recovery of vision and improvement in neuroimaging during corticosteroid treatment

Reinforcement with muscle, cotton, fibrin glue, or some other material is an alternative to clipping in some intracranial aneurysms; the surgeon must balance the need to create local inflammation (to reinforce the arterial wall) with the risk that the inflammation will spread and damage adjacent structures. Wrapping of clinical aneurysms, in particular, rarely may produce delayed and severe visual loss or ocular motor dysfunction. The clinical course and potential outcome of damage to the visual pathways, ocular motor tracts, or both remains controversial, as does the optimum management when visual loss occurs. We present the case of a patient who developed severe bilateral visual loss and neuroimaging evidence of inflammation in the paraclinoid and suprasellar regions 2 months after wrapping of bilateral clinoidal aneurysms with cotton and fibrin glue, but who recovered visual function and whose neuroimaging appearance improved after treatment with systemic corticosteroids.

Case report

A 61 year old woman underwent magnetic resonance imaging (MRI) and angiography after experiencing a minor stroke. The studies revealed aneurysms of the clinoidal portion of both internal carotid arteries. Endovascular treatment was unsuccessful. Accordingly, craniotomy was performed. As neither aneurysm could be clipped, both were wrapped with cotton gauze saturated with fibrin glue. The patient did well postoperatively until 2 months after surgery, when she noted blurred vision in the right eye. An incomplete left homonymous hemianopia associated with a mild right optic neuropathy was found, and MRI showed a thickened, nodular, enhancing area in the paraclinoid and suprasellar regions with involvement of both optic nerves and the optic chiasm. Observation was elected, but the patient developed a severe headache with worsening visual loss over the next 6 weeks. Repeat MRI showed an increase in the extent of the area of the enhancing process (fig 1A), and the patient was admitted to hospital.

At admission, visual acuity was 1/400 temporally in the right eye and 20/40 in the left eye. Colour vision was markedly diminished in both eyes. Kinetic perimetry showed an incomplete, incongruous left homonymous hemianopia (fig 2A). There was no relative afferent pupillary defect. Extraocular motility was normal, as were corneal and facial sensation. The right optic disc was minimally pale; the left optic disc appeared normal. Lumbar puncture showed normal cerebrospinal fluid glucose and protein levels; there were 14 mononuclear white blood cells. Complete blood count and serum chemistries were normal. An acute infectious aetiology was determined to be unlikely, and the patient was treated with intravenous dexamethasone 10 mg every 4 hours. Within 48 hours, visual acuity had improved to 20/20 in the left eye and 20/20 in the left eye, and the visual field of the right eye had expanded temporally. Intravenous dexamethasone was continued at 6 mg every 4 hours for 2 days, and then reduced to 4 mg every 4 hours. After 7 days of treatment, the patient’s visual acuity had improved to 20/40 in the right eye and to 20/20 in the left eye, with further expansion of the peripheral visual field of the right eye. Repeat MRI revealed marked reduction in the size and enhancement of the basal process.

The patient was discharged home on a 2 week tapering oral dose of dexamethasone.

Four weeks after discharge, the patient had visual acuity of 20/20 with slightly diminished colour vision in each eye. An incongruous, left homonymous hemianopia remained (fig 2B–C), but as this visual field deficit was scotomatous rather than absolute, the patient developed a severe headache with worsening visual loss over the next 6 weeks. Repeat MRI showed an increase in the extent of the area of the enhancing process (fig 1A), and the patient was admitted to hospital.

At admission, visual acuity was 1/400 temporally in the right eye and 20/40 in the left eye. Colour vision was markedly diminished in both eyes. Kinetic perimetry showed an incomplete, incongruous left homonymous hemianopia (fig 2A). There was no relative afferent pupillary defect. Extraocular motility was normal, as were corneal and facial sensation. The right optic disc was minimally pale; the left optic disc appeared normal. Lumbar puncture showed normal cerebrospinal fluid glucose and protein levels; there were 14 mononuclear white blood cells. Complete blood count and serum chemistries were normal. An acute infectious aetiology was determined to be unlikely, and the patient was treated with intravenous dexamethasone 10 mg every 4 hours. Within 48 hours, visual acuity had improved to 20/20 in the left eye and 20/20 in the left eye, and the visual field of the right eye had expanded temporally. Intravenous dexamethasone was continued at 6 mg every 4 hours for 2 days, and then reduced to 4 mg every 4 hours. After 7 days of treatment, the patient’s visual acuity had improved to 20/40 in the right eye and to 20/20 in the left eye, with further expansion of the peripheral visual field of the right eye. Repeat MRI revealed marked reduction in the size and enhancement of the basal process.

The patient was discharged home on a 2 week tapering oral dose of dexamethasone.

Four weeks after discharge, the patient had visual acuity of 20/20 with slightly diminished colour vision in each eye. An incongruous, left homonymous hemianopia remained (fig 2B–C), but as this visual field deficit was scotomatous rather than absolute, the patient developed a severe headache with worsening visual loss over the next 6 weeks. Repeat MRI showed an increase in the extent of the area of the enhancing process (fig 1A), and the patient was admitted to hospital.

At admission, visual acuity was 1/400 temporally in the right eye and 20/40 in the left eye. Colour vision was markedly diminished in both eyes. Kinetic perimetry showed an incomplete, incongruous left homonymous hemianopia (fig 2A). There was no relative afferent pupillary defect. Extraocular motility was normal, as were corneal and facial sensation. The right optic disc was minimally pale; the left optic disc appeared normal. Lumbar puncture showed normal cerebrospinal fluid glucose and protein levels; there were 14 mononuclear white blood cells. Complete blood count and serum chemistries were normal. An acute infectious aetiology was determined to be unlikely, and the patient was treated with intravenous dexamethasone 10 mg every 4 hours. Within 48 hours, visual acuity had improved to 20/20 in the left eye and 20/20 in the left eye, and the visual field of the right eye had expanded temporally. Intravenous dexamethasone was continued at 6 mg every 4 hours for 2 days, and then reduced to 4 mg every 4 hours. After 7 days of treatment, the patient’s visual acuity had improved to 20/40 in the right eye and to 20/20 in the left eye, with further expansion of the peripheral visual field of the right eye. Repeat MRI revealed marked reduction in the size and enhancement of the basal process.

The patient was discharged home on a 2 week tapering oral dose of dexamethasone.

Four weeks after discharge, the patient had visual acuity of 20/20 with slightly diminished colour vision in each eye. An incongruous, left homonymous hemianopia remained (fig 2B–C), but as this visual field deficit was scotomatous rather than absolute.
the patient had been able to return to driving and was now able to perform all of the activities of daily living. MRI 6 weeks after discharge showed no evidence of enhancement or mass effect in the parcellainous or suprasellar region (fig 1B). Two years after discharge and without further treatment, the patient remains well with stable vision and visual fields (fig 2D).

Comment

Reinforcement of unclippable intracranial aneurysms with autologous or alloplastic materials was proposed over 80 years ago, with subsequent studies showing that only a subset of these materials produce the desired local effect. Unfortunately, some patients in whom this treatment is used develop visual loss, occasionally several months or years after the surgery.7,8 Although both ischaemia and infection are thought to be inciting factors in some cases,9 most cases appear to result from an inflammatory reaction to the material used to wrap the aneurysm.7,8 The reason that the material incites such a reaction is unknown.

High quality MRI permits recognition of the inflammatory process that usually is found in cases of vision loss.4,5 Unlike in recent reports,6,6 our patient presented with a markedly enhancing bilateral process that, after corticosteroid treatment, diminished greatly in both size and degree of contrast enhancement, providing an anatomical correlation with the functional improvement demonstrated clinically. In our patient, therapy was initiated approximately 2 months after the visual loss ensued, as was treatment in other cases where no diminution of the inflammatory mass was seen. Thus, as noted by others,6 it seems clear that some patients recover spontaneously, some improve with steroid treatment, some improve with surgery, and some do not improve regardless of treatment.

To date, there has been no reported demonstration by MRI of size reduction of the inflammatory mass after medical therapy alone. We demonstrate here that cotton associated inflammation may respond dramatically to anti-inflammatory therapy both clinically and by neuroimaging. Furthermore, this case suggests that wrapping of intracranial aneurysms with cotton or cotton products reinforced with fibrin glue is justified in cases of vision loss,8,9 unlike in recent reports.6,6 Our patient presented with a markedly enhancing bilateral process that, after corticosteroid treatment, diminished greatly in both size and degree of contrast enhancement, providing an anatomical correlation with the functional improvement demonstrated clinically. In our patient, therapy was initiated approximately 2 months after the visual loss ensued, as was treatment in other cases where no diminution of the inflammatory mass was seen. Thus, as noted by others,6 it seems clear that some patients recover spontaneously, some improve with steroid treatment, some improve with surgery, and some do not improve regardless of treatment.

P S Subramanian, N R Miller
Department of Ophthalmology, The Johns Hopkins Hospital, 600 N Wolfe Street, Baltimore, MD 21287, USA

V Renard, R J Tamargo, N R Miller
Department of Neurosurgery, The Johns Hopkins Hospital, 600 N Wolfe Street, Baltimore, MD 21287, USA

Correspondence to: Prem S Subramanian, MD, Ophthalmology Service, Walter Reed Army Medical Center, 6900 Georgia Ave NW, Washington DC 20307-5001, USA; prem.subramanian@na.amedd.army.mil

MAILBOX

Visual loss may be due to silicone oil tamponade effect rather than silicone oil removal

We read with great interest the article by Caazaban et al.1 In all the three patients it would have been better to compare the visual acuity just before the silicone oil removal than immediate visual acuity after initial vitrectomy, because contact of the eye with the silicone oil could also be responsible for visual loss as it was known to cause optic nerve damage, as described in earlier reports.2 Earlier, Newsom et al also reported unexplained sudden visual loss following silicone oil removal in seven patients. They also observed only electrophysiological abnormalities.

Maybe the unexplained visual loss could be the result of optic nerve damage and diffuse ganglion cell dysfunction caused by a silicone oil tamponade effect on the eye rather than the procedure of silicone oil removal itself.

References


Visual loss after silicone oil removal

We read with interest the paper by Caazaban et al1 on the important emerging problem of sudden visual loss after removal of silicone oil. We have seen a similar pattern of visual loss in our own patients, typically in the macula on detachments associated with giant retinal tears. We have identified 12 cases in two units (St Thomas’s, London, and Sunderland Eye Infirmary), but five of these clearly had onset of visual loss before oil removal (onset between 1 month and 5 months after oil insertion).1 Further results of investigations are similar to those reported by Caazaban et al. In four of five pattern ERG was suggestive of macular dysfunction. The timing of onset of visual loss obviously alters the potential aetiology, which as stated is unknown.

In their paper, information on acuity for cases 2 and 3, between 1 week after oil insertion and oil removal is not provided. Did these cases have visual loss preceding oil removal? Developing cataract can obviously hinder interpretation of acuity measurements. In our cases the symptoms described did not fit with cataract (scotoma, red desaturation) and persisted if any cataract was removed.

We have seen a further case since this report, a 46 year old woman with a giant retinal tear and macula-on retinal detachment affecting the right eye. Acuity reduced during the period of tamponade from 6/6 at 2 weeks after oil insertion to 6/36+1, which did not recover after oil removal. She reported a central negative scotoma. Electrophysiology suggested macular dysfunction.

We have speculated that phototoxicity may have a role, as oil transmits light more in the blue spectrum than aqueous. The fat soluble macular pigments, lutein and zeaxanthin, are thought to protect the macula from phototoxic damage. Silicone oil has previously been reported to dissolve fat soluble elements from the retina.3

We measured the macular pigment optical density (MPOD) in this case using a modified confocal scanning laser ophthalmoscope and two wavelength autofluorescence technique 3 weeks after oil removal. The results showed a substantially reduced MPOD in the eye that had silicone oil compared to the fellow eye. Although the peak MPOD, at the foveal centre of both eyes was similar (0.47 right versus 0.52 left), the MPOD at 1/2 degree, 1 degree, and 2 degrees eccentric from the foveal centre was markedly lower in the eye that had silicone oil (0.12, 0.06, 0.02 respectively versus 0.40, 0.22, 0.07).

Although MPOD varies greatly between individuals, there is usually a macroscopically symmetry in normal eyes.4 Further work is required to determine whether or not this relates to the visual loss and whether...
therapeutic supplementation may reduce the risk of visual loss.  

E N Herbert, S H M Liew, T H Williamson  
Department of Ophthalmology, St Thomas’s Hospital,  
Lambeth Palace Road, London SE1 7EH, UK  

Correspondence to: Mr Edward N Herbert,  
Department of Ophthalmology, St Thomas’s Hospital,  
Lambeth Palace Road, London SE1 7EH, UK; enherbert@doctors.org.uk  

doi: 10.1136/bjo.2005.082610  

Accepted for publication 8 September 2005  

References  

Visual loss following silicone oil removal  

We congratulate Cazabon et al on their recent, well illustrated, report.1 Their cases reflect a similar group of seven patients we recently observed at Moorfields Eye Hospital. They were relatively young, 19–57 years old, had macula-on, or “just off” retinal detachments. Five of seven had giant retinal tears and the others multiple posterior tears with retinal detachment. Following vitrectomy and oil insertion, vision was good and then fell when the silicone oil was removed. The oil was in place for between 105–220 days; three patients had combined cataract surgery with oil removal.  

One difference between the reports is that vision in our group fell immediately following oil removal, whereas in Liverpool patients reported visual loss at 1 week. Visual loss could be severe, some lost vision to counting fingers with a relative afferent papillary defect, and all lost vision without macular signs, optical coherence tomographic, or angiographic changes.  

The interpretation of electrophysiological changes is different from that in our paper, where macular dysfunction was associated with generalised retinal dysfunction in some patients and with an optic neuropathy in one. In this paper only the macular function is commented on, the 30 Hz cone flicker being presented, and it is therefore difficult to compare data without the full ISCEV data.1  

It is not clear how the pattern visually evoked potential (VEP) can be “normal” in case 1, with a visual acuity of 6/36 and an abnormal pattern electroretinogram (PERG); even in macular disease with this level of visual acuity and an abnormal PERG, the pattern VEP is invariably abnormal.5  

A recent report of optic neuropathy induced by silicone oil may perhaps explain our findings in one case.6 However, all the other cases reported so far seem to point to a new as yet unexplained phenomenon of sudden visual loss following silicone oil removal. Photoreceptor apoptosis, triggered by rapid change in vitreous potassium concentrations, is an attractive theory, but more work is required to elucidate this phenomenon further. In the meantime we advocate a cautious approach to silicone oil in patients with macula-on detachments.  

R S B Newsom, R Johnston, P Sullivan, B Aylward, G Holder, Z Gregor  
Southampton Eye Unit, UK  

Correspondence to: Richard S B Newsom, Southampton Eye Unit, UK; richard.newsom@shbt.nhs.uk  

doi: 10.1136/bjo.2005.082644  

Accepted for publication 8 September 2005  

References  

19th International Society for Geographical & Epidemiological Ophthalmology Congress  

The 19th ISGEO congress will be held in Sao Paulo, Brazil on 18-19 February, 2006, just prior to the ICO. Abstract submission and registration forms can be obtained by emailing Dr Paul Courtright (pcourtright@kcco.net, url: ) or by accessing the ISGEO website at www.kcco.net/isgeo.  

Medical Contact Lens & Ocular Surface Association Winter Symposium  

The MCLOSA Winter Symposium will be held at the Western Eye Hospital, Marylebone Road, London NW1 on Friday 18 November 2005. For further information please visit the MCLOSA website at www.mclosa.org.uk/annualmtg.html.  

www.bjophthalmol.com
Intermittent exotropia increasing with near fixation: a "soft" sign of neurological disease

P H Phillips, K J Fray, M C Brodsky

Aim: To examine the association of distance-near disparity with neurological disease in children with intermittent exotropia.

Methods: A retrospective analysis was performed of the medical records of all children with intermittent exotropia examined at the Arkansas Children’s Hospital between 1989 and 2002. The study group consisted of children with intermittent exotropia who had a near deviation that exceeded the deviation at distance by at least 10 prism dioptres. The control group consisted of children with intermittent exotropia who had a distance deviation greater than or equal to the deviation at near. The main outcome measures were the prevalence of neurological abnormalities in the study and control groups.

Results: Among the 29 patients in the study group, 19 (66%) had a history of concurrent neurological abnormalities. Associated neurological conditions included developmental delay (10 patients), attention deficit disorder (four patients), cerebral palsy (four patients), history of intracranial haemorrhage (four patients), periventricular leucomalacia (three patients), seizures (two patients), cortical visual impairment (two patients), hydrocephalus (one patient), history of anoxic brain damage (one patient), history of encephalitis (one patient), and autism (one patient). Among the 37 patients in the control group, seven (19%) had a history of concurrent neurological abnormalities. The difference in the prevalence of neurological disease between the study group and the control group was significant (p = 0.0002).

Conclusion: Intermittent exotropia increasing with near fixation is associated with neurological disease in children.
was performed before evaluation by one of the investigators (one patient), and ocular motility measurements that were inconsistent (one patient).

The characteristics of the study and control groups are shown in table 1. The study and control groups did not differ significantly with respect to sex and age at evaluation. The 29 patients in the study group had intermittent exotropia that increased with near fixation with a mean deviation of 19 prism dioptres at distance and 35 prism dioptres at near. Seventeen of these 29 patients had an intermittent near deviation greater than or equal to 35 prism dioptres indicating robust fusional convergence amplitudes; 19 of these 29 patients (66%) had a history of concurrent neurological abnormalities as listed in table 2.

The control group consisted of 37 patients with a mean exodeviation of 30 prism dioptres at distance and 13 prism dioptres at near. Seven of these 37 patients (19%) had a history of concurrent neurological abnormalities as listed in table 2. The prevalence of neurological abnormalities was significantly higher in the patients who had an intermittent exotropia of 30 prism dioptres at distance and 13 prism dioptres at near. Seventeen of these 29 patients had an intermittent near deviation greater than or equal to 35 prism dioptres indicating robust fusional convergence amplitudes; 19 of these 29 patients (66%) had a history of concurrent neurological abnormalities as listed in table 2. The prevalence of neurological abnormalities was qualitatively similar between both groups.

**DISCUSSION**

We found a high prevalence of neurological disease in children with intermittent exotropia increasing at near fixation. Exodeviations that increase during near fixation have been associated with several neurological disorders including head trauma, dyslexia, Parkinson’s disease, congenital central hypoventilation syndrome, subdural haematoma, and stroke. The term “convergence insufficiency” has been loosely applied to this heterogeneous group of patients with exodeviations that become problematic during near fixation. In this context, apparent convergence insufficiency may arise from multiple mechanisms ranging from decreased fusional convergence amplitudes, a low accommodative convergence/accommodation ratio, accommodative insufficiency, poor convergence effort, poor accommodative effort, poor concentration, and pharmacological effects of medications. We are unable to assign a specific neurophysiological substrate to our study patients with intermittent exotropia that increases with near fixation. However, many of our study patients were able intermittently to fuse large exodeviations, demonstrating that their convergence amplitudes were greater than normal.

The magnitude of exodeviations at near is affected by accommodative and convergence effort. We encouraged accommodative and convergence effort by requiring our children to identify fixation targets as measurements were being obtained. However, we cannot exclude the possibility that reduced accommodative or convergence effort may have contributed to the high prevalence of exodeviations that increase with near fixation in children with neurological disease.

This study should be viewed in light of its inherent limitations. Firstly, because our cohort was gleaned from a children’s hospital population, our findings do not necessarily reflect the prevalence of neurological dysfunction in the general population. However, the increased prevalence of neurological disease in our children with intermittent exotropia that increases with near fixation compared with our control group of patients suggests that this association is real. Secondly, the prevalence of neurological disease was determined from a retrospective chart review. Not every patient was examined by a paediatric neurologist. However, patients and parents were routinely questioned regarding the presence of neurological disease at each visit. It is unlikely that a more detailed paediatric neurological evaluation would have disclosed clinically significant undiagnosed neurological disease in a significant number of our apparently healthy patients. Finally, we did not formally measure accommodative...
or convergence amplitudes in most of our patients with intermittent exotropia that increases with near fixation.

Our study confirms a high prevalence of neurological disease in children who have intermittent exotropia that increases with near fixation. However, no patient was subsequently found to have a serious treatable neurological lesion. As such, neuroimaging is not warranted, and further diagnostic evaluation can be guided by the clinical history. Although the determinants of increased near disparity in intermittent exotropia have yet to be defined, this form of strabismus appears to be a "soft" sign of neurological disease in children.

ACKNOWLEDGEMENT

Supported in part by unrestricted grant from Research to Prevent Blindness and the Pat & Willard Walker Eye Research Center, Jones Eye Institute, University of Arkansas for Medical Sciences.

Authors' affiliations

P H Phillips, K J Fray, M C Brodsky, Department of Ophthalmology, University of Arkansas for Medical Sciences, Little Rock, AR, USA

M C Brodsky, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA

Correspondence to: Paul H Phillips, MD, Arkansas Children’s Hospital, 800 Marshall Street, Little Rock, AR 72202, USA; phillippaulh@uams.edu

Accepted for publication 1 March 2005

REFERENCES